CFTR and cystic fibrosis: Laboratory evidence of this effect in different CFTR mutant cells, together with trial evidence for previously approved indications, allowed the FDA to conclude that the drug will work in several cystic fibrosis genotypes not tested in clinical trials.48 Such use of mechanistic evidence requires more than considering the biological plausibility of a treatment.